[
  {
    "ts": null,
    "headline": "CURE: Analysts Strike A Cautious Tone Heading Into 2026",
    "summary": "Discover why the Direxion Healthcare Bull 3X ETF is outperforming in 2025. Learn about key risks, returns, and buy ratings.",
    "url": "https://finnhub.io/api/news?id=a5ef5754831c30f25c83c66be5e038c5194b41554790fb800b0ad9b7a81a6a4b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764174517,
      "headline": "CURE: Analysts Strike A Cautious Tone Heading Into 2026",
      "id": 137615429,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2009808479/image_2009808479.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Discover why the Direxion Healthcare Bull 3X ETF is outperforming in 2025. Learn about key risks, returns, and buy ratings.",
      "url": "https://finnhub.io/api/news?id=a5ef5754831c30f25c83c66be5e038c5194b41554790fb800b0ad9b7a81a6a4b"
    }
  },
  {
    "ts": null,
    "headline": "Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock?",
    "summary": "KYMR hits a 52-week high as optimism builds around KT-621's progress and upcoming data in atopic dermatitis.",
    "url": "https://finnhub.io/api/news?id=130cbf96f5242dd6798beb98b319ba096427cfcbba9eee89052e8b3d4849c0f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764160380,
      "headline": "Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock?",
      "id": 137612613,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "KYMR hits a 52-week high as optimism builds around KT-621's progress and upcoming data in atopic dermatitis.",
      "url": "https://finnhub.io/api/news?id=130cbf96f5242dd6798beb98b319ba096427cfcbba9eee89052e8b3d4849c0f1"
    }
  }
]